Sort
35,931 grants matching “parkinsons”
SUMO family Ubiquitin-like Modifiers In Higher Eukaryotes
$624,929Mary C. Dasso · Child Health And Human Development · Z01 · FY2007 · HD
CLINICAL CORE
$624,771Edward Y. Zamrini · University Of Alabama At Birmingham · P50 · FY2007 · AG
Development of soluble epoxide hydrolase inhibitors for the treatment of Alzheimer's disease
$624,696Kin Sing Stephen Lee · Michigan State University · R01 · FY2024 · AG
-Omics driven network analysis in Lewy Body dementia
$624,533Owen A Ross · Mayo Clinic Jacksonville · U54 · FY2021 · NS
-Omics driven network analysis in Lewy Body dementia
$624,533Owen A Ross · Mayo Clinic Jacksonville · U54 · FY2020 · NS
-Omics driven network analysis in Lewy Body dementia
$624,533Owen A Ross · Mayo Clinic Jacksonville · U54 · FY2023 · NS
-Omics driven network analysis in Lewy Body dementia
$624,533Owen A Ross · Mayo Clinic Jacksonville · U54 · FY2022 · NS
Predicting progression of human prion disease
$624,529Michael D Geschwind · University Of California, San Francisco · R01 · FY2014 · AG
Development of Drugs Acting at Adenosine Receptors
$624,412Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2019 · DK
Neurophysiological biomarkers in preclinical assays of risk propensity
$624,368Stephanie C Dulawa · University Of California, San Diego · R56 · FY2024 · MH
Neuronal FXR as a potential therapeutic target for Alzheimer's disease
$624,323Julie Kay Andersen · Buck Institute For Research On Aging · R01 · FY2023 · AG
Dysregulation of Histone Acetylation in Parkinson's Disease
$624,231Frank Soldner · Albert Einstein College Of Medicine · R56 · FY2023 · NS
Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads
$624,004John M Littleton · Naprogenix, Inc · R44 · FY2020 · NS
Brain and Genetic Predictors of Individual Differences in Pain and Placebo Analgesia
$623,968Naomi P. Friedman · University Of Colorado · R01 · FY2021 · DA
Research Project III: RNP-CRISPR to Treat Huntington's Disease
$623,889Niren Murthy · University Of California Berkeley · U19 · FY2025 · NS
Resource Core II: In Vivo Core
$623,888Piotr Hadaczek · University Of California Berkeley · U19 · FY2025 · NS
Molecular Mechanisms Controlling Formation of Basal Ganglia Circuitry
$623,859Kenneth J Campbell · Cincinnati Childrens Hosp Med Ctr · R01 · FY2018 · MH
Development and Validation of a Self-Efficacy Item Bank
$623,839Lisa M. Shulman · University Of Maryland Baltimore · U01 · FY2011 · AR
Metabolomics and risk of Parkinson's Disease
$623,653Alberto Ascherio · Harvard School Of Public Health · R01 · FY2019 · NS
Targeted disruption the enzymes of O-GlcNAc cycling: Animal models of Disease
$623,618John A. Hanover · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2014 · DK
KIR and HLA effects in CNS paraneoplastic syndromes and related neuroimmune conditions
$623,609Emmanuel J Mignot · Stanford University · U01 · FY2024 · NS
Imaging of Neuropsychiatric Disorders with Developmental and Genetic Mechanisms
$623,605Karen Faith Berman · National Institute Of Mental Health · ZIA · FY2009 · MH
TWINS AND RISK OF PD: A CLINICAL AND IMAGING STUDY
$623,590Parkinson'S Institute · R01 · FY2003 · NS
Non-invasive and Long-lived CNS Delivery of Treg-inducing Cytokine Depots
$623,579Peter M Tessier · University Of Michigan At Ann Arbor · R01 · FY2025 · EB
Leucine rich repeat kinase 2 and dominantly inherited Parkinson disease
$623,570Mark Cookson · National Institute On Aging · ZIA · FY2013 · AG